Novo Nordisk A/SNVONYSE
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank0
3Y CAGR-25.4%
5Y CAGR-8.5%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-25.4%/yr
vs +17.0%/yr prior
5Y CAGR
-8.5%/yr
Recent deceleration
Acceleration
-42.4pp
Decelerating
Percentile
P0
Near historical low
vs 5Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 5.01 | -49.2% |
| 2024 | 9.87 | -27.0% |
| 2023 | 13.53 | +12.0% |
| 2022 | 12.08 | -0.2% |
| 2021 | 12.10 | +54.7% |
| 2020 | 7.82 | +5.3% |
| 2019 | 7.43 | +15.3% |
| 2018 | 6.45 | -10.9% |
| 2017 | 7.24 | +29.3% |
| 2016 | 5.60 | - |